DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025" report to their offering.
Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregular and often abnormally fast heart rate. Various therapeutic options are available to treat patients with AF, and most patients will receive some form of antithrombotic therapy, a heart rate control agent, and potentially an antiarrhythmic drug for rhythm control.
All sectors of the AF market have historically been saturated with generics, with the vitamin K antagonists such as warfarin playing an important role in stroke prevention in AF. However, since 2010, and the launch of the first of the new oral anticoagulants (NOACs), a shift in the treatment of patients with AF has occurred. The NOACs offer a significant advancement in anticoagulation and their continued uptake will be the main driver of growth in the AF market over the next 10 years.
In contrast, despite a great unmet need for safer antiarrhythmic drugs, developments in this field are expected to be much slower and there are presently no late-stage drug candidates that are expected to address this unmet need during the forecast period.
Key Questions Answered
- The anticoagulant market for stroke prevention in AF has become increasingly crowded. How will the drug treatment landscape for AF change? Which of the NOACs will become the market leader over the next ten years? What are the key drivers and barriers to this change?
- The AF market is marked by the presence of a number of unmet needs. What are the main unmet needs in the treatment of AF? Will the drugs under development fulfil the unmet needs of the AF market?
- Will any late-stage anticoagulants drugs make a significant impact on the AF market? What subgroups of the AF population will they target?
Key Topics Covered:
1 Tables & Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Need and Opportunity
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
11 Appendix
Companies Mentioned
- Boehringer Ingelheim
- Bayer
- Janssen (Johnson & Johnson)
- Bristol-Myers Squibb
- Pfizer
- Daiichi-Sankyo
-
Armetheon
For more information about this report visit http://www.researchandmarkets.com/research/rhsskl/pharmapoint
